DCR PHXC

Drug Profile

DCR PHXC

Alternative Names: DCR-PHXC

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Oxalate modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Primary hyperoxaluria

Most Recent Events

  • 07 Dec 2017 Phase-I clinical trials in Primary hyperoxaluria in United Kingdom (SC)
  • 02 Nov 2017 Dicerna Pharmaceuticals plans to file an IND application with the US FDA for Primary hyperoxaluria in 1Q 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top